A Study of Abemaciclib in Healthy Participants



Status:Completed
Conditions:Healthy Studies
Therapuetic Areas:Other
Healthy:No
Age Range:18 - 70
Updated:1/6/2019
Start Date:February 2016
End Date:July 2016

Use our guide to learn which trials are right for you!

A Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Determine the Exposure-Response Relationship Between Abemaciclib and QT Interval in Healthy Subjects

The purposes of this study are to determine:

- The effect of single increasing doses of the study drug, abemaciclib, on healthy
participants.

- The relationship between the amount of abemaciclib and the electrical tracing of the
heart rhythm when abemaciclib is given.

- How much abemaciclib is found in the bloodstream and how long the body takes to get rid
of it.

Information about any side effects that occur will be collected. The study will enroll two
groups (cohorts) of participants. Each group will complete 4 study periods. This study is
expected to last about 3 months. Screening may occur up to 28 days prior to enrollment. All
participants will undergo a follow-up assessment approximately 21 days after administration
of their final dose of study drug.


Inclusion Criteria:

- Overtly healthy males or females, as determined by medical history and physical
examination

- Male participants will be sterile

- Female participants must not be of childbearing potential

Exclusion Criteria:

- Have known allergies to abemaciclib, related compounds, or any components of the
formulation

- Have an abnormality in the 12-lead electrocardiogram (ECG) including a Fridericia's
corrected QT interval (QTcF) greater than 450 milliseconds (ms) (males) or greater
than 470 ms (females)

- Have a history or presence of cardiovascular, respiratory, hepatic, renal,
gastrointestinal, endocrine, hematological, or neurological disorders capable of
significantly altering the absorption, metabolism, or elimination of drugs

- Have a gastrointestinal disorder causing clinically significant symptoms such as
nausea, vomiting, and diarrhea, or malabsorption syndromes, or constipation

Additional Exclusion Criterion for Participants Enrolled in Cohort 2:

- Have a known hypersensitivity to loperamide hydrochloride or to any of the excipients
We found this trial at
2
sites
Daytona Beach, Florida 32117
Principal Investigator: Hugh Coleman
Phone: 386-366-6400
?
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Evansville, Indiana 47710
Principal Investigator: Kelly Whitehurst
Phone: 812-474-5000
?
mi
from
Evansville, IN
Click here to add this to my saved trials